Niemi M - Search Results

1

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M; Clinical Pharmacogenomics Implementation Consortium (CPIC). Wilke RA, et al. Among authors: niemi m. Clin Pharmacol Ther. 2012 Jul;92(1):112-7. doi: 10.1038/clpt.2012.57. Epub 2012 May 23. Clin Pharmacol Ther. 2012. PMID: 22617227 Free PMC article.

2

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.

Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT. Igel M, et al. Among authors: niemi m. Clin Pharmacol Ther. 2006 May;79(5):419-26. doi: 10.1016/j.clpt.2006.01.010. Epub 2006 Apr 11. Clin Pharmacol Ther. 2006. PMID: 16678544 Clinical Trial.

3

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

Niemi M, Pasanen MK, Neuvonen PJ. Niemi M, et al. Clin Pharmacol Ther. 2006 Oct;80(4):356-66. doi: 10.1016/j.clpt.2006.06.010. Clin Pharmacol Ther. 2006. PMID: 17015053 Clinical Trial.

4

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

Neuvonen PJ, Niemi M, Backman JT. Neuvonen PJ, et al. Among authors: niemi m. Clin Pharmacol Ther. 2006 Dec;80(6):565-81. doi: 10.1016/j.clpt.2006.09.003. Clin Pharmacol Ther. 2006. PMID: 17178259 Review.

5

Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.

Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Pasanen MK, et al. Among authors: niemi m. Clin Pharmacol Ther. 2007 Dec;82(6):726-33. doi: 10.1038/sj.clpt.6100220. Epub 2007 May 2. Clin Pharmacol Ther. 2007. PMID: 17473846

6

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.

Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Kalliokoski A, et al. Among authors: niemi m. J Clin Pharmacol. 2008 Mar;48(3):311-21. doi: 10.1177/0091270007311569. Epub 2008 Jan 10. J Clin Pharmacol. 2008. PMID: 18187595 Clinical Trial.

7

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. Keskitalo JE, et al. Among authors: niemi m. Clin Pharmacol Ther. 2009 Aug;86(2):197-203. doi: 10.1038/clpt.2009.79. Epub 2009 May 27. Clin Pharmacol Ther. 2009. PMID: 19474787 Clinical Trial.

8

Transporter pharmacogenetics and statin toxicity.

Niemi M. Niemi M. Clin Pharmacol Ther. 2010 Jan;87(1):130-3. doi: 10.1038/clpt.2009.197. Epub 2009 Nov 4. Clin Pharmacol Ther. 2010. PMID: 19890253 Review.

9

International Transporter Consortium commentary on clinically important transporter polymorphisms.

Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, Huang SM, Sugiyama Y, Weitz D, Wen Y, Xia CQ, Yee SW, Zimdahl H, Niemi M; International Transporter Consortium. Giacomini KM, et al. Among authors: niemi m. Clin Pharmacol Ther. 2013 Jul;94(1):23-6. doi: 10.1038/clpt.2013.12. Clin Pharmacol Ther. 2013. PMID: 23778707

10

PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. Aquilante CL, et al. Among authors: niemi m. Pharmacogenet Genomics. 2013 Dec;23(12):721-8. doi: 10.1097/FPC.0b013e3283653b27. Pharmacogenet Genomics. 2013. PMID: 23962911 Free PMC article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

546 results

Search Page